Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CPIX 
Cumberland Pharmaceuticals Inc (CPIX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: CPIX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8.5
1 Year Target Price $8.5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 20.54% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 50.27M USD | Price to earnings Ratio - | 1Y Target Price 8.5 |
Price to earnings Ratio - | 1Y Target Price 8.5 | ||
Volume (30-day avg) 1 | Beta -0.41 | 52 Weeks Range 1.04 - 7.25 | Updated Date 10/14/2025 |
52 Weeks Range 1.04 - 7.25 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.22 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -6.97% | Operating Margin (TTM) -6.9% |
Management Effectiveness
Return on Assets (TTM) -2.55% | Return on Equity (TTM) -10.89% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 42723907 | Price to Sales(TTM) 1.19 |
Enterprise Value 42723907 | Price to Sales(TTM) 1.19 | ||
Enterprise Value to Revenue 1.02 | Enterprise Value to EBITDA 12.23 | Shares Outstanding 14959937 | Shares Floating 7965718 |
Shares Outstanding 14959937 | Shares Floating 7965718 | ||
Percent Insiders 41.59 | Percent Institutions 24.77 |
Upturn AI SWOT
Cumberland Pharmaceuticals Inc
Company Overview
History and Background
Cumberland Pharmaceuticals Inc. was founded in 1999 and is headquartered in Nashville, Tennessee. The company focuses on the acquisition, development, and commercialization of branded prescription products. A significant milestone was the FDA approval of Acetadote for acetaminophen overdose. Over time, Cumberland has grown its product portfolio through internal development and acquisitions.
Core Business Areas
- Hospital Products: Cumberland's hospital products are mainly injectable products sold to hospitals. These products often address critical care needs such as acetaminophen overdose and other acute conditions.
- Gastroenterology Products: Products targeting gastrointestinal conditions, such as constipation and inflammatory bowel disease, are another core focus. These products provide therapeutic options for patients with various GI disorders.
- Women's Health Products: Cumberland offers products in the women's health space.
Leadership and Structure
Cumberland Pharmaceuticals is led by A.J. Kazimi, the Chief Executive Officer. The organizational structure includes various departments focused on research and development, sales and marketing, finance, and operations.
Top Products and Market Share
Key Offerings
- Acetadote: Acetadote is an intravenous acetylcysteine product used to treat acetaminophen overdose. Competitors include generic acetylcysteine products and other liver support treatments. Revenue contribution is significant but not publicly disclosed. Market share is difficult to pinpoint due to variations in generic availability and hospital purchasing decisions.
- Caldolor: Caldolor is an intravenous ibuprofen product used for pain and fever reduction. Competitors include generic IV ibuprofen and other IV pain medications. Market share data is not readily available but Caldolor has become a significant revenue driver for Cumberland.
- Kristalose: Kristalose is a prescription laxative used to treat constipation. Competitors include other prescription and over-the-counter laxatives. Market share data not publicly available.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, high R&D costs, stringent regulatory requirements, and patent protection. Trends include increasing generic drug penetration, biosimilar development, and a focus on specialty pharmaceuticals.
Positioning
Cumberland Pharmaceuticals occupies a niche position, focusing on acquiring and developing specialized products often targeting hospital settings. Their competitive advantage lies in their expertise in developing and commercializing these types of products and niche market segments.
Total Addressable Market (TAM)
The TAM for Cumberland's product categories is multi-billion, including pain management, liver disease, and gastrointestinal treatments. Cumberland targets specific subsegments within these larger markets, going for less competition on niche products.
Upturn SWOT Analysis
Strengths
- Specialized product portfolio
- Established hospital presence
- Experienced management team
- Strategic acquisitions
Weaknesses
- Limited product pipeline
- Reliance on key products
- Small market capitalization
- Dependence on third-party manufacturing
Opportunities
- Acquisitions of complementary products
- Expansion into new therapeutic areas
- Geographic expansion
- Strategic partnerships
Threats
- Generic competition
- Regulatory changes
- Pricing pressures
- Product liability lawsuits
Competitors and Market Share
Key Competitors
- ENDP
- TEVA
- MYL
Competitive Landscape
Cumberland Pharmaceuticals faces competition from larger pharmaceutical companies and generic manufacturers. Their advantage lies in their focus on niche products and hospital markets. Their disadvantage is smaller size and limited resources compared to larger competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is tied to product sales and acquisitions. Past performance should be obtained from SEC filings.
Future Projections: Future growth projections are based on analyst estimates. These estimates vary depending on product pipeline and market conditions and can be found on financial websites such as Yahoo Finance or Bloomberg.
Recent Initiatives: Recent initiatives may include product acquisitions, clinical trials, and strategic partnerships. These are discussed in the company's press releases and investor presentations.
Summary
Cumberland Pharmaceuticals is a niche pharmaceutical company focused on hospital products and select therapeutic areas. Their strength lies in their specialized portfolio, but they face challenges from larger competitors and generic erosion. Strategic acquisitions and successful product development are crucial for their future growth. Cumberland should focus on expanding its pipeline and diversifying its revenue streams.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Cumberland Pharmaceuticals Inc. SEC Filings
- Company Website
- Financial News Sources (e.g., Yahoo Finance, Bloomberg)
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share data is estimated and may not be precise. Always conduct thorough research and consult with a financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cumberland Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Nashville, TN, United States | ||
IPO Launch date 2009-08-11 | Founder, Chairman, President & CEO Mr. A. J. Kazimi MBA | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 91 | Website https://www.cumberlandpharma.com |
Full time employees 91 | Website https://www.cumberlandpharma.com | ||
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, an injection for the prevention of nausea and vomiting for patients receiving chemotherapy treatment; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of the cardiomyopathy associate with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, and aspirin-exacerbated respiratory disease; and is in Phase II clinical trial for the treatment of systemic sclerosis and idiopathic pulmonary fibrosis. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.